Skip to main content
Figure 4 | Journal of Neuroinflammation

Figure 4

From: CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord

Figure 4

Intrathecal administration of fluorocitrate or SP600125 reverses TCI-induced upregulation of CXCL12 protein in the spinal cord. (A) Confocal images show inhibitory effect of fluorocitrate on induction of astrocytic marker GFAP (green) after TCI. Original magnification: ×200. (B) Mean green immunofluorescence intensity of GFAP of A among sham, TCI and TCI + Fluorocitrate group. For control experiments, saline was used. Fluorocitrate (1 nmol/10 μl, i.t.) or saline (10 μl, i.t.) was given once a day on postoperative days 8, 9 and 10, respectively. Tissues were collected 4 hours after the last spinal injection (n = 5 in each group). *P < 0.05, **P < 0.01 versus sham + saline. ##P < 0.01 versus TCI + saline. (C) Western blot and data summary show inhibitory effect of fluorocitrate on TCI-induced increased expression of CXCL12 protein (n = 4 in each group). (D) Western blot and data summary show inhibitory effect of SP600125 on TCI-induced increased expression of CXCL12 protein (n = 4 in each group). SP600125 (20 nmol/10 μl, i.t.) or DMSO (for control, 10 μl, i.t.) was given once a day on postoperative days 8, 9 and 10, respectively. Tissues were collected 6 hours after the last spinal injection. **P < 0.01 versus sham + DMSO. ##P < 0.01 versus TCI + DMSO.

Back to article page